Redeye comments on Lipum’s announcement of the finalized Clinical Study Report (CSR) for the phase I trial with lead candidate SOL-116. The data further validate earlier topline results, reinforcing our positive outlook on the candidate’s safety, pharmacokinetics, and target engagement. We view this milestone as a strong foundation for phase II development and believe that SOL-116 continues to show promise as a novel treatment for rheumatoid arthritis.
LÄS MER
